Vertex has top orphan drug in the pipeline, as pharma eyes shiny obesity drugs: report

Vertex’s cystic fibrosis triple combo is poised to become the top selling orphan drug in terms of net present value, amid shifting sentiments in the pharma industry for rare disease drugs, according to Evaluate.

VX-121, or the “Vanza Triple,” which combines a new molecule called vanzacaftor with Vertex’s already…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks